Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COVID-19 mRNA vaccine - Biocad

Drug Profile

COVID-19 mRNA vaccine - Biocad

Latest Information Update: 06 Apr 2020

At a glance

  • Originator Biocad
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 26 Mar 2020 COVID-19 mRNA vaccine - BIOCAD is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html
  • 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in Russia (parenteral)
  • 19 Mar 2020 Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020

Development Overview

Introduction

An mRNA based vaccine to prevent SARS-COV-2 (COVID-2019) coronavirus infections is being developed by Biocad. Early research is underway in the Russia.

Biocad is looking partnership opportunities for the development of the vaccine (BIOCAD website, March 2020).

Key Development Milestones

As of March 2020, early research is ongoing in Russia for COVID-19 vaccine [1]

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class RNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections SARS-COV-2 Prevention Research Russia Parenteral / unspecified Biocad 23 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Biocad Originator Russia
Biocad Owner Russia

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Biocad - Unspecified - 23 Mar 2020

Future Events

Expected Date Event Type Description Updated
30 Apr 2020 Trial Update Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020 [1] 30 Mar 2020

Development History

Event Date Update Type Comment
26 Mar 2020 Licensing Status COVID-19 mRNA vaccine - BIOCAD is available for licensing as of 23 Mar 2020. https://biocadglobal.com/partnership.html Updated 06 Apr 2020
23 Mar 2020 Phase Change Early research in COVID-2019 infections (Prevention) in Russia (parenteral) [1] Updated 06 Apr 2020
19 Mar 2020 Trial Update Biocad plans a first preclinical trial in COVID-2019 infections (Prevention) in April 2020 [1] Updated 06 Apr 2020

References

  1. BIOCAD started working on mRNA vaccine against coronavirus.

    Media Release
Back to top